Related references
Note: Only part of the references are listed.Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome
Angela Fischer et al.
HEMATOLOGICAL ONCOLOGY (2018)
Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses
Tiziana Vaisitti et al.
CANCER RESEARCH (2018)
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Michael Y. Choi et al.
CELL STEM CELL (2018)
On the architecture of translational research designed to control chronic lymphocytic leukemia
Michael Hallek
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
J. Yu et al.
LEUKEMIA (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A ROR1 HER3 IncRNA signalling axis modulates the Hippo YAP pathway to regulate bone metastasis
Chunlai Li et al.
NATURE CELL BIOLOGY (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
Jian Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Bing Cui et al.
BLOOD (2016)
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Fu Li et al.
CANCER RESEARCH (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Richter syndrome: pathogenesis and management
Davide Rossi et al.
SEMINARS IN ONCOLOGY (2016)
Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
Michael Y. Choi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice
George F. Widhopf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
ROR1, an embryonic protein with an emerging role in cancer biology
Nicholas Borcherding et al.
PROTEIN & CELL (2014)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova et al.
BLOOD (2013)
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz et al.
BLOOD (2013)
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
Amir Hossein Daneshmanesh et al.
LEUKEMIA & LYMPHOMA (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
Suping Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia
Vincent T. Bicocca et al.
CANCER CELL (2012)
NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma
Tomoya Yamaguchi et al.
CANCER CELL (2012)
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Suping Zhang et al.
PLOS ONE (2012)
Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies
Hema Dave et al.
PLOS ONE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Davide Rossi et al.
BLOOD (2011)
ROR1 expression is not a unique marker of CLL
Gabor Barna et al.
HEMATOLOGICAL ONCOLOGY (2011)
Ror-Family Receptor Tyrosine Kinases in Noncanonical Wnt Signaling: Their Implications in Developmental Morphogenesis and Human Diseases
Yasuhiro Minami et al.
DEVELOPMENTAL DYNAMICS (2010)
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
Sivasubramanian Baskar et al.
CLINICAL CANCER RESEARCH (2008)
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a
Tetsuya Fukuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development
R Al-Shawi et al.
DEVELOPMENT GENES AND EVOLUTION (2001)
Share Paper
